Glecirasib

Glecirasib
Clinical data
Drug class	KRAS G12C inhibitor
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-yl-3-pyridinyl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile;
CAS Number	2657613-87-9;
PubChem CID	157827766;
Chemical and physical data
Formula	C31H26ClF4N7O2
Molar mass	640.04 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N;
	InChI InChI=1S/C31H26ClF4N7O2/c1-5-19(44)41-8-10-42(11-9-41)29-16-12-18(32)27(20-21(33)22(34)23(35)24(36)25(20)38)40-30(16)43(31(45)17(29)13-37)28-15(4)6-7-39-26(28)14(2)3/h5-7,12,14H,1,8-11,38H2,2-4H3; Key:QRRJEUIQLZNPIO-UHFFFAOYSA-N;

Glecirasib (JAB-21822) is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the G12C mutant version of the enzyme KRAS. It is used as a combination treatment alongside other selective enzyme inhibitors.^[1]^[2]^[3]^[4]

References

^ Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, et al. (March 2025). "Glecirasib in KRAS^G12C-mutated nonsmall-cell lung cancer: a phase 2b trial". Nature Medicine. 31 (3): 894–900. doi:10.1038/s41591-024-03401-z. PMID 39762419.
^ Dong P, Ni J, Zheng X, Wang M, Yang M, Han H (June 2025). "Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future". European Journal of Pharmacology. 996 177428. doi:10.1016/j.ejphar.2025.177428. PMID 40024323.
^ Li J, Wang Z, Huang J, Ba Y, Cao B, Luo S, et al. (February 2026). "Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS^G12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials". The Lancet. Gastroenterology & Hepatology. 11 (2): 110–123. doi:10.1016/S2468-1253(25)00267-5. PMID 41344351.
^ Li J, Deng T, Gu Y, Calles Blanco A, Li Z, Bai C, et al. (November 2025). "Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials". Cancer Communications. 45 (11): 1500–1512. doi:10.1002/cac2.70056. PMC 12629856. PMID 41037823.

[1] Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, et al. (March 2025). "Glecirasib in KRAS^G12C-mutated nonsmall-cell lung cancer: a phase 2b trial". Nature Medicine. 31 (3): 894–900. doi:10.1038/s41591-024-03401-z. PMID 39762419.

[2] Dong P, Ni J, Zheng X, Wang M, Yang M, Han H (June 2025). "Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future". European Journal of Pharmacology. 996 177428. doi:10.1016/j.ejphar.2025.177428. PMID 40024323.

[3] Li J, Wang Z, Huang J, Ba Y, Cao B, Luo S, et al. (February 2026). "Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS^G12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials". The Lancet. Gastroenterology & Hepatology. 11 (2): 110–123. doi:10.1016/S2468-1253(25)00267-5. PMID 41344351.

[4] Li J, Deng T, Gu Y, Calles Blanco A, Li Z, Bai C, et al. (November 2025). "Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials". Cancer Communications. 45 (11): 1500–1512. doi:10.1002/cac2.70056. PMC 12629856. PMID 41037823.

[1]

[2]

[3]

[4]